Lewis Clayton Jr. Cantley Sells 1,000 Shares of Agios Pharmaceuticals, Inc. (AGIO) Stock

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Director Lewis Clayton Jr. Cantley sold 1,000 shares of the firm’s stock in a transaction dated Monday, October 16th. The stock was sold at an average price of $71.09, for a total value of $71,090.00. Following the completion of the sale, the director now directly owns 84,394 shares in the company, valued at $5,999,569.46. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Lewis Clayton Jr. Cantley also recently made the following trade(s):

  • On Tuesday, October 17th, Lewis Clayton Jr. Cantley sold 4,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $71.10, for a total value of $284,400.00.
  • On Wednesday, September 13th, Lewis Clayton Jr. Cantley sold 1,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $65.47, for a total value of $65,470.00.
  • On Thursday, September 14th, Lewis Clayton Jr. Cantley sold 4,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $65.59, for a total value of $262,360.00.
  • On Wednesday, August 23rd, Lewis Clayton Jr. Cantley sold 4,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $56.85, for a total value of $227,400.00.
  • On Thursday, July 20th, Lewis Clayton Jr. Cantley sold 9,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $56.36, for a total value of $507,240.00.

Agios Pharmaceuticals, Inc. (AGIO) traded down 1.51% during midday trading on Friday, reaching $64.43. The company’s stock had a trading volume of 506,575 shares. The stock has a 50 day moving average of $67.58 and a 200 day moving average of $57.44. Agios Pharmaceuticals, Inc. has a 52 week low of $39.24 and a 52 week high of $72.73. The firm’s market capitalization is $3.12 billion.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.57) by ($0.21). The company had revenue of $11.30 million for the quarter, compared to analyst estimates of $10.68 million. Agios Pharmaceuticals had a negative return on equity of 68.15% and a negative net margin of 502.12%. The firm’s quarterly revenue was up 62.1% on a year-over-year basis. During the same quarter last year, the company posted ($1.47) earnings per share. On average, equities research analysts predict that Agios Pharmaceuticals, Inc. will post ($7.08) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Lewis Clayton Jr. Cantley Sells 1,000 Shares of Agios Pharmaceuticals, Inc. (AGIO) Stock” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright laws. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2017/10/27/agios-pharmaceuticals-inc-agio-director-lewis-clayton-jr-cantley-sells-1000-shares.html.

Several equities analysts have recently weighed in on AGIO shares. SunTrust Banks, Inc. reaffirmed a “buy” rating and issued a $80.00 price objective on shares of Agios Pharmaceuticals in a research note on Wednesday, October 4th. JPMorgan Chase & Co. reissued a “buy” rating and set a $76.00 price target on shares of Agios Pharmaceuticals in a research report on Monday, September 18th. Canaccord Genuity set a $90.00 price target on Agios Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, August 8th. BidaskClub raised Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, July 13th. Finally, Needham & Company LLC boosted their price target on Agios Pharmaceuticals from $54.00 to $72.00 and gave the stock a “buy” rating in a research report on Thursday, August 10th. Three research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Agios Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $75.20.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Pictet Asset Management Ltd. increased its holdings in Agios Pharmaceuticals by 198.9% in the third quarter. Pictet Asset Management Ltd. now owns 54,700 shares of the biopharmaceutical company’s stock valued at $3,651,000 after purchasing an additional 36,400 shares during the period. Nationwide Fund Advisors increased its holdings in Agios Pharmaceuticals by 37.8% in the third quarter. Nationwide Fund Advisors now owns 6,344 shares of the biopharmaceutical company’s stock valued at $423,000 after purchasing an additional 1,740 shares during the period. Fox Run Management L.L.C. acquired a new stake in Agios Pharmaceuticals in the third quarter valued at $574,000. Mutual of America Capital Management LLC increased its holdings in Agios Pharmaceuticals by 25.1% in the third quarter. Mutual of America Capital Management LLC now owns 30,356 shares of the biopharmaceutical company’s stock valued at $2,026,000 after purchasing an additional 6,100 shares during the period. Finally, Lord Abbett & CO. LLC increased its holdings in Agios Pharmaceuticals by 81.5% in the second quarter. Lord Abbett & CO. LLC now owns 266,910 shares of the biopharmaceutical company’s stock valued at $13,733,000 after purchasing an additional 119,836 shares during the period. Institutional investors and hedge funds own 93.89% of the company’s stock.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Insider Buying and Selling by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply